Sucrosomial Iron in Patients With Celiac Disease and IDA

Sucrosomial Iron Supplementation in Anaemic Patients With Celiac Disease Not Tolerating Oral Ferrous Sulfate

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02916654

Enrollment

Registered

2016-09-27

Start date

2015-04-30

Completion date

2017-12-31

Last updated

2017-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease, Iron Deficiency Anemia

Brief summary

Sucrosomial iron (Sideral® Forte) is a preparation of ferric pyrophosphate conveyed within a phospholipid membrane associated with ascorbic acid, is a new-generation oral iron which shows a high gastrointestinal absorption and high bioavailability with a low incidence of side effects due to lack of any direct contact with intestinal mucosa. In comparison with the other standard oral iron preparations, sucrosomial iron seems to be a promising new strategy of iron replacement in CD patients.

Interventions

DIETARY_SUPPLEMENTsucrosomial iron

administration of sucrosomial iron

DRUGSulphate iron

administration of sulphate iron

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* proven celiac disease * iron deficiency anemia

Exclusion criteria

* other autoimmne diseases * pregnancy psychiatric disorders

Design outcomes

Primary

Measure	Time frame
Hemoglobin	3 months

Countries

Italy

Contacts

Primary ContactLuca Elli, MD

dottorlucaelli@gmail.com0255033384

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026